Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 2/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.97 |
| ▸ | SRC known ✓ | P12931 | 2/20 | 0.97 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.97 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.74 |
| ▸ | LCK known ✓ | P06239 | 3/20 | 0.74 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.73 |
| ▸ | FBP1 | P09467 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | MAPT | P10636 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | GAK | O14976 | 1/20 | 0.97 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CDK1 | P06493 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30362813 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KDRFBP1 | |
| Hydrochloric Acid SCHEMBL29369196 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL29444884 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL30363011 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL9423 | 0.99 | EGFR (1.00) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL12963484 | 0.92 | FBP1 (0.91) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL8349430 | 0.91 | EGFR (0.91) | EGFRERBB2ERBB4KDRFBP1 | |
| Hydrochloric Acid SCHEMBL28028745 | 0.91 | EGFR (0.98) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL4232360 | 0.90 | FBP1 (0.84) | EGFRERBB2ERBB4KDRFBP1 | |
| SCHEMBL22367416 | 0.90 | FBP1 (1.00) | EGFRERBB2ERBB4KDRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250262213-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12336995-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2007056135-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056244-A2 | METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| WO-2006110608-A2 | COMPOSITIONS AND METHOD FOR INCREASING THE EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262213-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB4 14/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | EGFR 176/4885ERBB2 288/4885ERBB4 974/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | EGFR 54/4885ERBB2 216/4885ERBB4 524/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EGFR 176/4885ERBB2 288/4885ERBB4 974/4885 |
| US-12336995-B2 | Combination therapies | KRAS, NRAS, HRAS | EGFR 4/4885ERBB2 5/4885ERBB4 18/4885 |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | EGFR 3142/4885ERBB2 1565/4885ERBB4 1542/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | EGFR 2685/4885ERBB2 2449/4885ERBB4 2444/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EGFR 176/4885ERBB2 288/4885ERBB4 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.